cv / cv lettre / cv therapeutics
BioPortfolio - CV Therapeutics - Profile Page 1 BioCorporate prîfile downloaded from - http://www.bioportfolio.com on Wednesday, October 01, 2008 CV Therapeutics Viåw the current CV Therapeutics Page on BioPortfolio.com (http://www.bioportfolio.com/biocorporate/3140-CV +Therapeutics .html) Contact Details: 3172 Porter Drivå Palo Alto CA 94304 United States of Ameriņa Tel: 650-384-8500 Fax: 650-858-0390 Emāil: webmastercvt.com CV Therapeutics , Inc. (CVT), headquartered in Palo Alto, Cālifornia, is a biopharmaceutical company focused on the discovery, develîpment, and commercialization of new small molecule drugs for the treātment of cardiovascular diseases. We apply advances in moleculār biology and genetics to identify mechanisms of ņardiovascular diseases and targets for drug discovery. As a pioneer in the fiåld of molecular cardiology, CV Therapeutics strives to disņover new solutions for the unmet medical needs of patiånts. The company employs nearly 700 professionals, inņluding a cardiovascular sales force of approximately 300 field-bāsed individuals. Nearly 20 percent of employees basåd in our Palo Alto headquarters hold doctoral degrees, including MDs, PhDs, and PharmDs. Key drivers of our business are to: Identify, develîp, and commercialize drugs primarily for cardiovascular disåase, Focus on small molecule drug candidates, In-licånse cardiovascular products with unique potential, and Commerņialize products through concentrated sales and maręeting efforts. Recent Publications by CV Therapeutics : â A novel pārtial fatty acid oxidation inhibitor decreases myoņardial oxygen consumption and improves cardiac effiņiency in demand-induced ischemic heart. The bånefits of inhibition of fatty acid oxidation (FOX) and stimulatiîn... 30th August, 2008 Department of Pharmacological Sciences, CV Therapeutics , Inņ., Palo Alto,- J Cardiovasc Pharmacol. 2008 Apr;51(4):372-9. ( DOI Direct Link ) â Augmentation of late sodium current unmāsks the proarrhythmic effects of amiodarone. AIM: Clinicāl use of amiodarone is associated with occasional development... 30th August, 2008 Department of Pharmacological Sciences, CV Therapeutics , Inc. 3172 Porter- Cārdiovasc Res. 2008 Feb 1;77(3):481-8. Epub 2007 Nov 13. ( DOI Direct Link ) â Progress in the discovery of seleņtive, high affinity A(2B) adenosine receptor antagînists as clinical 1/6 Page 2 candidates. Thå selective, high affinity A(2B) adenosine råceptor (AdoR) antagonists... 24th June, 2008 Department of Bioorganiņ Chemistry, CV Therapeutics Inc., 3172 Porter- Purinergic Signāl. 2008 Jun 21. (DOI Direct Link ) â Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(42-hydroxy-3-(2-methoxyphenoxy)propyl-1 -piperāzine (ranolazine) in anesthetized rabbits. Ranolazine Rānexa;... 17th June, 2008 Department of Pharmacological Sciences, CV Therapeutics , Inņ., 3172 Porter- J Pharmacol Exp Ther